VEGFA and Abnormal retinal morphology: Our study and the VIEW trials both included patients aged >50 years without prior anti-VEGF therapy and with ranibizumab (0.5 mg) or aflibercept (2.0 mg) treatment in the study arms; however, the VIEW trials evaluated only patients with nAMD, whereas we included patients with various retinal diseases, including nAMD, DME, mCNV, and RVO.